Delivering antibiotics to the lungs of patients with ventilator-associated pneumonia: An update

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 5, 2013, Pages 511-521

  Luyt, Charles Edouard ^a,b   Bréchot, Nicolas ^a,b   Combes, Alain ^a,b   Trouillet, Jean Louis ^a,b   Chastre, Jean ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

aerosol; amikacin; antibiotic; colistin; ventilator associated pneumonia; vibrating mesh nebulizer

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; CEFTAZIDIME; COLISTIMETHATE; COLISTIN; GENTAMICIN; HELIUM; IMIPENEM; OXYGEN; PLACEBO; POLYMYXIN; SALBUTAMOL; TOBRAMYCIN; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; AEROSOL; ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; BREATH SYNCHRONIZATION; BREATHING; BREATHING CIRCUIT; BRONCHOSPASM; COUGHING; CYSTIC FIBROSIS; DISAGREEABLE TASTE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TISSUE LEVEL; HUMAN; JET NEBULIZER; LEGAL ASPECT; LUNG PARENCHYMA; MUCOSA INFLAMMATION; NEBULIZER; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESPIRATORY AIRFLOW; REVIEW; SIDE EFFECT; TASTE; TIDAL VOLUME; TREATMENT DURATION; ULTRASONIC NEBULIZER; VENTILATOR; VENTILATOR ASSOCIATED PNEUMONIA; VIBRATING MESH NEBULIZER;

ACINETOBACTER; ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVENOUS; AEROSOLS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; LUNG; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NEBULIZERS AND VAPORIZERS; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84877044444     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.13.36     Document Type: Review

References (76)

1. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340(1), 23-30 (1999
2. Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-Associated pneumonia. Respir. Care 52(7), 866-884 (2007
3. Dhand R. Aerosol delivery during mechanical ventilation: From basic techniques to new devices. J. Aerosol Med. Pulm. Drug Deliv. 21(1), 45-60 (2008
4. Waldrep JC, Berlinski A, Dhand R. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer. J. Aerosol Med. 20(3), 310-319 (2007
5. Waldrep JC, Dhand R. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr. Drug Deliv. 5(2), 114-119 (2008
6. Luyt CE, Clavel M, Guntupalli K et al. Pharmacokinetics and lung delivery of PDDS-Aerosolized amikacin (NKTR-061 in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit. Care 13(6), R200 (2009
7. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospitalacquired, ventilator-Associated, and healthcare-Associated pneumonia. Am. J. Respir. Crit. Care Med. 171(4), 388-416 (2005
8. Palmer LB. Aerosolized antibiotics in critically ill ventilated patients. Curr. Opin. Crit. Care 15(5), 413-418 (2009
9. Luyt CE, Combes A, Nieszkowska A, Trouillet JL, Chastre J. Aerosolized antibiotics to treat ventilator-Associated pneumonia. Curr. Opin. Infect. Dis. 22(2), 154-158 (2009
10. Valcke YJ, Vogelaers DP, Colardyn FA, Pauwels RA. Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 101(4), 1028-1032 (1992
11. Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-Associated pneumonia. Chest 128(2), 545-552 (2005
12. Boselli E, Breilh D, Djabarouti S et al. Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in ritically ill patients. Intensive Care Med. 33(9), 1519-1523 (2007
13. Boselli E, Breilh D, Cannesson M et al. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 30(5), 976-979 (2004
14. Boselli E, Breilh D, Rimmelé T et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-Acquired pneumonia. Crit. Care Med. 33(1), 104-109 (2005
15. Boselli E, Breilh D, Rimmelé T et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 30(5), 989-991 (2004
16. Boselli E, Breilh D, Saux MC, Gordien JB, Allaouchiche B. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-Associated pneumonia. Intensive Care Med. 32(12), 2059-2062 (2006
17. Badia JR, Soy D, Adrover M et al. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J. Antimicrob. Chemother. 54(2), 508-514 (2004
18. Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, García MS. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 38(2), 263-271 (2012
19. Lu Q, Luo R, Bodin L et al.; Nebulized Antibiotics Study Group. Efficacy of high-dose nebulized colistin in ventilatorassociated pneumonia caused by multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 117(6), 1335-1347 (2012
20. Goldstein I, Wallet F, Robert J, Becquemin MH, Marquette CH, Rouby JJ. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am. J. Respir. Crit. Care Med. 165(2), 171-175 (2002
21. Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH, Rouby JJ. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am. J. Respir. Crit. Care Med. 166(10), 1375-1381 (2002
22. Ferrari F, Lu Q, Girardi C et al.; Experimental ICU Study Group. Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa. Intensive Care Med. 35(10), 1792-1800 (2009
23. Lu Q, Girardi C, Zhang M et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 36(7), 1147-1155 (2010
24. Falagas ME, Agrafiotis M, Athanassa Z, Siempos II. Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Rev. Anti. Infect. Ther. 6(4), 447-452 (2008
25. Michalopoulos A, Fotakis D, Virtzili S et al. Aerosolized colistin as adjunctive treatment of ventilator-Associated pneumonia due to multidrug-resistant Gram-negative bacteria: A prospective study. Respir. Med. 102(3), 407-412 (2008
26. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: A review of the recent literature. Clin. Med. Res. 4(2), 138-146 (2006).
27. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis. 41(5), 754-757 (2005
28. Berlana D, Llop JM, Fort E, Badia MB, Jódar R. Use of colistin in the treatment of multiple-drug-resistant Gram-negative infections. Am. J. Health. Syst. Pharm. 62(1), 39-47 (2005
29. Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: Experience in a tertiary care hospital in northern Taiwan. J. Microbiol. Immunol. Infect. 43(4), 323-331 (2010
30. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Ieven M. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa. BMC Infect. Dis. 11, 317 (2011
31. Pérez-Pedrero MJ, Sánchez-Casado M, Rodríguez-Villar S. [Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients]. Med. Intensiva 35(4), 226-231 (2011
32. Kofteridis DP, Alexopoulou C, Valachis A et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-Associated pneumonia: A matched case-control study. Clin. Infect. Dis. 51(11), 1238-1244 (2010
33. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-Associated pneumonia caused by Gram-negative bacteria. J. Antimicrob. Chemother. 65(12), 2645-2649 (2010
34. Michalopoulos A, Papadakis E. Inhaled anti-infective agents: Emphasis on colistin. Infection 38(2), 81-88 (2010).
35. Athanassa ZE, Markantonis SL, Fousteri MZ et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 38(11), 1779-1786 (2012
36. Luyt CE, Eldon MA, Stass H, Gribben D, Corkery K, Chastre J. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with Gram-negative pneumonia and acute renal failure. J. Aerosol Med. Pulm. Drug Deliv. 24(4), 183-190 (2011
37. Le Conte P, Potel G, Peltier P et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am. Rev. Respir. Dis. 147(5), 1279-1282 (1993
38. Le Conte P, Potel G, Clémenti E et al. [Administration of tobramycin aerosols in patients with nosocomial pneumonia: A preliminary study]. Presse Med. 29(2), 76-78 (2000
39. Czosnowski QA, Wood GC, Magnotti LJ et al. Adjunctive aerosolized antibiotics for treatment of ventilator-Associated pneumonia. Pharmacotherapy 29(9), 1054-1060 (2009
40. Palmer LB, Smaldone GC, Chen JJ et al. Aerosolized antibiotics and ventilatorassociated tracheobronchitis in the intensive care unit. Crit. Care Med. 36(7), 2008-2013 (2008
41. Luyt CÉ, Combes A, Trouillet JL, Nieszkowska A, Chastre J. Virus-induced acute respiratory distress syndrome: Epidemiology, management and outcome. Presse Med. 40(12 Pt 2), e561-e568 (2011
42. Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ; Nebulized Antibiotics Study Group. Nebulized ceftazidime and amikacin in ventilator-Associated pneumonia caused by Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 184(1), 106-115 (2011
43. Zarrilli GM, Monteforte M, Baram D, Daroowalla F, Smaldone GC, Palmer LB. Systemic versus aerosolized delivery of vancomycin for MRSA: Concentrations in lungs and serum. Am. J. Respir. Crit. Care Med. Abstract 177, A286 (2008
44. Miller DD, Amin MM, Palmer LB, Shah AR, Smaldone GC. Aerosol delivery and modern mechanical ventilation: In vitro/in vivo evaluation. Am. J. Respir. Crit. Care Med. 168(10), 1205-1209 (2003).
45. Loffert DT, Ikle D, Nelson HS. A comparison of commercial jet nebulizers. Chest 106(6), 1788-1792 (1994
46. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 110(2), 498-505 (1996
47. Harvey CJ, O'Doherty MJ, Page CJ, Thomas SH, Nunan TO, Treacher DF. Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation. Eur. Respir. J. 10(4), 905-909 (1997
48. Steckel H, Eskandar F. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur. J. Pharm. Sci. 19(5), 443-455 (2003
49. Pitance L, Vecellio L, Leal T, Reychler G, Reychler H, Liistro G. Delivery efficacy of a vibrating mesh nebulizer and a jet nebulizer under different configurations. J. Aerosol Med. Pulm. Drug Deliv. 23(6), 389-396 (2010
50. Ferrari F, Liu ZH, Lu Q et al. Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: Ultrasonic versus vibrating plate nebulizers. Intensive Care Med. 34(9), 1718-1723 (2008
51. O'Riordan TG, Palmer LB, Smaldone GC. Aerosol deposition in mechanically ventilated patients. Optimizing nebulizer delivery. Am. J. Respir. Crit. Care Med. 149(1), 214-219 (1994
52. Newman SP. How well do in vitro particle size measurements predict drug delivery in vivo? J. Aerosol Med. 11(Suppl 1), S97-S104 (1998
53. Newman SP, Chan HK. In vitro/in vivo comparisons in pulmonary drug delivery. J. Aerosol Med. Pulm. Drug Deliv. 21(1), 77-84 (2008
54. Phipps PR, Gonda I. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest 97(6), 1327-1332 (1990
55. Rao N, Kadrichu N, Ament B. Application of a droplet evaporation model to aerodynamic size measurement of drug aerosols generated by a vibrating mesh nebulizer. J. Aerosol Med. Pulm. Drug Deliv. 23(5), 295-302 (2010
56. Hess DR, Dillman C, Kacmarek RM. In vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: Pressure-control vs. volume control ventilation. Intensive Care Med. 29(7), 1145-1150 (2003
57. Dolovich MA. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir. Care 45(6), 597-608 (2000).
58. Fink JB, Dhand R, Grychowski J, Fahey PJ, Tobin MJ. Reconciling in vitro and in vivo measurements of aerosol delivery from a metered-dose inhaler during mechanical ventilation and defining efficiency-enhancing factors. Am. J. Respir. Crit. Care Med. 159(1), 63-68 (1999
59. Ensminger SA, Morales IJ, Peters SG et al. The hospital mortality of patients admitted to the ICU on weekends. Chest 126(4), 1292-1298 (2004
60. O'Doherty MJ, Thomas SH, Page CJ, Treacher DF, Nunan TO. Delivery of a nebulized aerosol to a lung model during mechanical ventilation. Effect of ventilator settings and nebulizer type, position, and volume of fill. Am. Rev. Respir. Dis. 146(2), 383-388 (1992
61. O'Riordan TG, Greco MJ, Perry RJ, Smaldone GC. Nebulizer function during mechanical ventilation. Am. Rev. Respir. Dis. 145(5), 1117-1122 (1992
62. Harvey CJ, O'Doherty MJ, Page CJ, Thomas SH, Nunan TO, Treacher DF. Effect of a spacer on pulmonary aerosol deposition from a jet nebuliser during mechanical ventilation. Thorax 50(1), 50-53 (1995
63. Ari A, Areabi H, Fink JB. Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. Respir. Care 55(7), 837-844 (2010
64. Tonnellier M, Ferrari F, Goldstein I, Sartorius A, Marquette CH, Rouby JJ. Intravenous versus nebulized ceftazidime in ventilated piglets with and without experimental bronchopneumonia: Comparative effects of helium and nitrogen. Anesthesiology 102(5), 995-1000 (2005
65. Martin AR, Ang A, Katz IM, Häussermann S, Caillibotte G, Texereau J. An in vitro assessment of aerosol delivery through patient breathing circuits used with medical air or a helium-oxygen mixture. J. Aerosol Med. Pulm. Drug Deliv. 24(5), 225-234 (2011
66. Ehrmann S, Mercier E, Vecellio L, Ternant D, Paintaud G, Dequin PF. Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects. Intensive Care Med. 34(4), 755-762 (2008
67. Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: Delivery and response. Crit. Care Med. 26(1), 31-39 (1998
68. Elman M, Goldstein I, Marquette CH, Wallet F, Lenaour G, Rouby JJ; Experimental ICU Study Group. Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology 97(1), 199-206 (2002
69. Levy J, Smith AL, Kenny MA, Ramsey B, Schoenknecht FD. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: Comparison with activity in serum. J. Infect. Dis. 148(6), 1069-1076 (1983
70. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 132(4), 761-765 (1985
71. Todisco T, Eslami A, Baglioni S et al. Basis for nebulized antibiotics: Droplet characterization and in vitro antimicrobial activity versus Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. J. Aerosol Med. 13(1), 11-16 (2000
72. Diot P, Gagnadoux F, Martin C et al. Nebulization and anti-Pseudomonas aeruginosa activity of colistin. Eur. Respir. J. 10(9), 1995-1998 (1997
73. Feeley TW, Du Moulin GC, Hedley- Whyte J, Bushnell LS, Gilbert JP, Feingold DS. Aerosol polymyxin and pneumonia in seriously ill patients. N. Engl. J. Med. 293(10), 471-475 (1975
74. Chastre J, Wolff M, Fagon JY et al. PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilatorassociated pneumonia in adults: A randomized trial. JAMA 290(19), 2588-2598 (2003
75. Kuhn RJ. Formulation of aerosolized therapeutics. Chest 120(3 Suppl.), 94S-98S (2001
76. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J. Aerosol Med. Pulm. Drug Deliv. 21(1), 71-76 (2008